Ox­ford Bio­med­ica's next CEO to start in March; Kåre Schultz ready to wrap up Te­va tenure ear­ly

→ Frank Math­ias is call­ing it quits as CEO of Ger­man CD­MO Rentschler Bio­phar­ma, mov­ing in­stead to UK gene and cell ther­a­py play­er Ox­ford Bio­med­ica in March 2023. At that time, he’ll al­so re­turn to the fa­mil­iar con­fines of the Rentschler su­per­vi­so­ry board, which he first joined in 2013 be­fore vault­ing to CEO three years lat­er. Ox­ford Bio­med­ica’s long­time CEO John Daw­son re­tired in Jan­u­ary, and in­ter­im chief Roch Do­liveux will get to fo­cus sole­ly on his role as chair­man once Math­ias ar­rives.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.